about
Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment ChoicesDimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsSystematic Review of Pharmacological Properties of the Oligodendrocyte LineageA Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future PerspectivesPrecision Medicine in Multiple Sclerosis: Future of PET Imaging of Inflammation and Reactive AstrocytesNeuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation.Differences in common heritable blood immune cell populations may underlie MS susceptibility and progression.Galectin-8 as an immunosuppressor in experimental autoimmune encephalomyelitis and a target of human early prognostic antibodies in multiple sclerosis.Specific Depletion of Myelin-Reactive B Cells via BCR-Targeting.Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.A potent and selective C-11 labeled PET tracer for imaging sphingosine-1-phosphate receptor 2 in the CNS demonstrates sexually dimorphic expression.Low-level laser therapy ameliorates disease progression in a mouse model of multiple sclerosis.Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS)The Association Between Genetic Polymorphism rs703842 in CYP27B1 and Multiple Sclerosis: A Meta-AnalysisNatalizumab Therapy Modulates miR-155, miR-26a and Proinflammatory Cytokine Expression in MS Patients.Researchers Expand Focus on Progressive Forms Of Multiple Sclerosis: Efforts to Pinpoint the Beginning of Disease May Yield Clues to Treatment.Variants of MicroRNA Genes: Gender-Specific Associations with Multiple Sclerosis Risk and SeverityA high throughput drug screening assay to identify compounds that promote oligodendrocyte differentiation using acutely dissociated and purified oligodendrocyte precursor cells.Development of a high throughput drug screening assay to identify compounds that protect oligodendrocyte viability and differentiation under inflammatory conditionsInflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple SclerosisCo-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor CellsInvestigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived ImmunoglobulinsAbsence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis Patients.Platelets Play Differential Role During the Initiation and Progression of Autoimmune Neuroinflammation.Therapeutic Advances and Future Prospects in Progressive Forms of Multiple SclerosisAn older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosis.Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.Comparison of Sleep Problems in Individuals with Spinal Cord Injury and Multiple SclerosisMultiple sclerosis and primary vascular dysregulation (Flammer syndrome)Neural Stem Cells Engineered to Express Three Therapeutic Factors Mediate Recovery from Chronic Stage CNS AutoimmunityCD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation StudyMetabolomic signatures associated with disease severity in multiple sclerosisOpportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases.Microglia Responses in Acute and Chronic Neurological Diseases: What Microglia-Specific Transcriptomic Studies Taught (and did Not Teach) Us.Epigenetics in NG2 glia cells.Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis.Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.
P2860
Q26748229-74F1308C-F0D7-401A-9391-6004B45C48DBQ26752859-958B71DA-7FB2-48CE-ADAD-810E72564965Q26768210-FBD74ED2-C611-4BB9-A3E1-D7352E886C7AQ28068709-475F9873-0BBF-4EB3-98FF-4F0DEB7B42D9Q28078621-28C0AD74-8CDA-41E4-94F0-74CB85578715Q30699740-B70B3FB9-F7AA-46AF-B66D-4F6AC326BE4BQ33673956-2C1A5B22-E34C-4F40-B30D-5F2C797E02C0Q33692526-591C0043-B50C-4C53-9895-E175640D9AABQ33834605-EFF3D93A-4A97-41A8-B7CA-47874711ED22Q35721504-BC26BAFA-89F3-449C-BDDF-B65FB576A7AEQ35722755-A4AE80CD-4B94-48C9-9776-D2976F13C2FCQ35868052-D3060763-0290-4084-BA06-52133215A67CQ35878169-F38B8832-5913-486F-AF6F-1383B55ED331Q36008726-48BDF33D-B22B-4982-9141-CD66ED2012BFQ36016728-83049AE5-F06F-43EF-AB13-18398188370EQ36054501-E567258A-1ED0-46D8-B1DD-E7A3BCD5C7BBQ36065033-CD1F3C22-9B07-412E-AF41-976351F41508Q36088780-E0895AB9-03A4-41D4-805F-8F8B0940618DQ36122722-85DA7183-5C76-47B5-ACB8-CC06555E83FFQ36133389-2EB92887-0C62-4A8B-A0D0-05D3745BA665Q36247618-4B7EA7E6-51A9-41A8-933F-9ED5411C2527Q36290946-34138CB5-DCB6-4128-95FE-E0084A005EB4Q36330016-884DBC78-1B21-4D4B-A119-46AA3987A37EQ36348434-38741DF1-161B-43A7-A047-5A58135F6175Q36455070-65E0C9D9-10D1-4097-A8B5-C832C2388656Q36471613-288C6C1C-B0D5-4A35-B739-E80DDC48DBA2Q36484443-71761867-A7E9-42B1-B7BA-97A0F1AF09ECQ36794075-30CC15EA-4EFB-4BE8-A580-545FAA4102BDQ36821577-6072CB21-4024-411A-9B1B-DC46500DD874Q36897062-0DFB0AD7-CB14-4B8C-922D-6771DF948C5FQ37006428-4320A6CA-174B-4EC6-A6C8-48E66C9F06B7Q37256159-531BBD3B-B910-47D8-A893-02972D7F566BQ37368151-F5290F3D-2844-4D22-9979-E685D7EA579DQ37613281-7C4CE3C4-BBCC-4DB4-BA61-4D6B0069AB26Q37670027-1845DEC6-2811-4952-A3BD-2D5C3E8CD8CCQ38430287-988F60C2-5EBE-4C3C-B68E-AD6A3D764E5AQ38532591-A0DD7CFD-5FFF-4713-A4AD-A5794D64B7F9Q38558344-4279A731-A245-4663-9301-AB5DBAF1EBECQ38639337-02689548-97DC-4FEB-B84E-20280C0F2573Q38663577-421E3B11-FE6C-457D-8BD2-74A560470E02
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Multiple sclerosis-a quiet revolution
@ast
Multiple sclerosis-a quiet revolution
@en
Multiple sclerosis-a quiet revolution
@nl
type
label
Multiple sclerosis-a quiet revolution
@ast
Multiple sclerosis-a quiet revolution
@en
Multiple sclerosis-a quiet revolution
@nl
prefLabel
Multiple sclerosis-a quiet revolution
@ast
Multiple sclerosis-a quiet revolution
@en
Multiple sclerosis-a quiet revolution
@nl
P2860
P3181
P356
P1476
Multiple sclerosis-a quiet revolution
@en
P2093
Claudia F. Lucchinetti
Richard M. Ransohoff
P2860
P2888
P304
P3181
P356
10.1038/NRNEUROL.2015.14
P407
P577
2015-03-01T00:00:00Z
P5875
P6179
1009524229